AnaptysBio, Inc.
ANABHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, AnaptysBio, Inc. (ANAB) is listed under Biotechnology. The company carries a $1.46B market cap, placing it firmly in the small-cap category. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis.
Market Cap
$1.46B
Beta
0.45
P/E (TTM)
—
P/E (Fwd)
9.61
EPS (TTM)
$-0.97
EPS (Fwd)
$5.07
ROE
—
ROA
—
Cash
$164.1M
Total Debt
$269.6M
Free CF
—
52W Change
108.4%
Annual Financials
Cash vs Debt
Where ANAB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ANAB finished 9.80% below its 150-day moving average ($54.59) and 0.73% below its 200-day moving average ($49.60). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ANAB overbought or oversold?
At the October 20, 2026 close, ANAB's RSI(14) was 46.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ANAB has $164.1M in cash with $269.6M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Revenue has grown from $63.2M (2021) to $234.6M (2025), reflecting a 271% increase over the period.
With a beta below 0.7, AnaptysBio, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence AnaptysBio, Inc.'s trajectory.